IGM Biosciences (NASDAQ:IGMS) Given New $2.00 Price Target at Truist Financial
IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...
IGM Biosciences Stock: Bad News With No Turnaround In Sight
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
BioSpace2d
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
IGM Biosciences (NASDAQ:IGMS) Given “Hold” Rating at Jefferies Financial Group
IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies ...
Fintel on MSN1d
Stifel Downgrades IGM Biosciences (IGMS)
Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...
IGM Bio plunges as Wall Street downgrades on portfolio shakeup
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
IGM Biosciences downgraded to Hold from Buy at Jefferies
Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...
IGM Biosciences price target lowered to $2 from $12 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...
GlobalData on MSN2d
IMG Biosciences enacts massive lay-offs after Phase I trial failure
Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.